US EditionHuman Adipose Depots’ Diverse Functions and Dysregulations During Cardiometabolic Disease
- Ascletis completed dosing all participants in its U.S. clinical study for obesity treatment, which combines ASC47 and Semaglutide.
- The study evaluates safety, tolerability, and preliminary efficacy of ASC47, which has a half-life of up to 40 days, in 28 participants with obesity.
- Topline data from the study are expected in the fourth quarter of 2025, reflecting rapid enrollment and interest in obesity treatments.
- In a DIO mouse model, ASC47 combined with Semaglutide showed a 56.7% greater reduction in body weight compared to Semaglutide alone.
56 Articles
56 Articles
Human adipose depots’ diverse functions and dysregulations during cardiometabolic disease
Adipose tissue depots develop specific functions in a location dependent manner. In humans, this for example includes thermogenic capacity in the brown adipose supraclavicular, deep neck and perirenal depots, healthy lipid storage primarily in the gluteofemoral subcutaneous depot, and immunogenic support in the visceral omental depot. These distinct functions are at some point programmed into adipose progenitor cells, which retain some of the ph…
The Berkshire Eagle
Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously administered ASC47 (half-life up to 40 days) in combination with four doses of…
Coverage Details
Bias Distribution
- 59% of the sources are Center
To view factuality data please Upgrade to Premium
